# TetraVitae Bioscience

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tetravitae-bioscience

- Industry: Renewable Energy
- Headquarters: Chicago, US
- Website: www.tetravitae.com
- Total disclosed funding: $9.2M
- Latest round: Series A (Oct 14, 2010)
- Investors on record: 3

## About

TetraVitae Bioscience is a biotechnology firm focusing on innovative solutions for the life sciences sector. The company develops advanced bioproducts and technologies aimed at enhancing sustainability and performance across various applications.TetraVitae Bioscience specializes in biotechnology and is based in Chicago, US. The company was acquired by Eastman Chemical Company in November 2011. The acquisition marked a strategic pivot aimed at integrating TetraVitae's advanced biotechnologies into Eastman's expansive product portfolio. Illinois Ventures and RPM Ventures were key investors in TetraVitae's most recent funding round, which was a Series A round that raised USD 2.870 mn, bringing the total amount raised to USD 2.870 mn. The current company valuation stands at USD 15.646 mn.TetraVitae Bioscience focuses on developing innovative bioproducts that cater to diverse sectors including healthcare and sustainability. Their products are crafted using advanced biotechnological processes, offering unique solutions that align with environmental sustainability goals. The company aims to provide tailored solutions to clients, enhancing product performance while minimizing ecological impact.TetraVitae Bioscience's revenue model is centered around B2B transactions, supplying specialized bioproducts to manufacturers in the life sciences and sustainability sectors. They engage in long-term agreements with clients, ensuring steady supply chains and support for their advanced biotechnological solutions. Revenue is generated through direct sales of bioproducts, enabling clients to benefit from innovative, high-performance offerings that address specific market needs.TetraVitae Bioscience plans to expand its product offerings with new biotechnologies aimed at enhancing sustainability in various industries. The company is targeting new markets across North America and Europe, with specific plans to launch their latest bioproducts by the end of 2023. The recent Series A funding round will be utilized to support product development and market expansion initiatives, allowing TetraVitae to leverage its advanced technologies to meet growing industry demands.

## Funding rounds

- Series A, Oct 14, 2010, $2.9M — Illinois Ventures, RPM Ventures
- Series A, Nov 30, 2008, $6.3M — Illinois Ventures, 180 Degree Capital, RPM Ventures

## Investors

- Illinois Ventures (https://capitalatlas.ai/funds/illinois-ventures) — Series A
- 180 Degree Capital (https://capitalatlas.ai/funds/180-degree-capital) — Series A
- RPM Ventures (https://capitalatlas.ai/funds/rpm-ventures) — Series A